Cargando…
Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
Among non-dialysis-dependent chronic kidney disease (ND-CKD) patients, a low hematopoietic response to erythropoiesis-stimulating agents (ESAs) is a predictor for poor renal and cardiovascular outcome. To assess the method for evaluating hyporesponsiveness to ESA in patients with ND-CKD, a multicent...
Autores principales: | Narita, Ichiei, Hayashi, Terumasa, Maruyama, Shoichi, Masaki, Takao, Nangaku, Masaomi, Nishino, Tomoya, Sato, Hiroshi, Sofue, Tadashi, Wada, Takashi, Imai, Enyu, Iwasaki, Manabu, Mizuno, Kyoichi, Hase, Hiroki, Kamouchi, Masahiro, Yamamoto, Hiroyasu, Kagimura, Tatsuo, Tanabe, Kenichiro, Kato, Hideki, Wada, Takehiko, Usui, Tomoko, Akizawa, Tadao, Hirakata, Hideki, Tsubakihara, Yoshiharu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707758/ https://www.ncbi.nlm.nih.gov/pubmed/36445882 http://dx.doi.org/10.1371/journal.pone.0277921 |
Ejemplares similares
-
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)
por: Kato, Hideki, et al.
Publicado: (2017) -
Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan
por: Hayashi, Terumasa, et al.
Publicado: (2020) -
Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
por: Maruyama, Shoichi, et al.
Publicado: (2023) -
Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan
por: Tanaka, Tetsuhiro, et al.
Publicado: (2018) -
A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study
por: Akizawa, Tadao, et al.
Publicado: (2021)